Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

Feasibility And Benefit Of Molecularly-Informed Enrollment Into Early Phase Clinical Trials For Patients With Relapsed Or Refractory Diffuse Large B-Cell Lymphoma

J. Michot,V. Camara-Clayette, A. Detolle,C. Chahine,J. Lazarovici,A. Danu,J. Bosq,D. Ghez, P. Romano-Martin,P. Dartigues,J. Arfi-Rouche,R. Bahleda, W. Rahali,A. Varga,C. Baldini,L. Tselikas, C. Paume, H. Lecourt,S. Cotteret,V. Vergé, J. Soria,C. Massard,V. Ribrag

BLOOD（2018）

Cited 0|Views16
No score
Abstract
Background: Patients with relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL) often do poorly with conventional salvage regimens of chemotherapy. Next-generation sequencing (NGS) panels can rapidly identify recurrent molecular abnormalities, thus helping to orient patients (pts) in appropriate targeted therapies or clinical trials. We aimed to evaluate whether selecting pts through tumor genotyping is associated with a better outcome.
More
Translated text
Key words
lymphoma,early phase clinical trials,clinical trials,molecularly-informed,b-cell
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined